High-Flow Nasal Oxygen Vs Standard Oxygen Therapy in Immunocompromised Patients with Acute Respiratory Failure: A Meta-Analysis of Randomized Controlled Trials

Author(s):  
B. Kheiri ◽  
Y. Zayed ◽  
M. Barbarawi ◽  
A. Aburahma ◽  
I. Gakhal ◽  
...  
2021 ◽  
Vol 10 (1) ◽  
Author(s):  
Hsin-Yi Liu ◽  
Ka-Wai Tam ◽  
El-Wui Loh ◽  
Wan-Chi Liu ◽  
Hsien-Cheng Kuo ◽  
...  

Abstract Background Procedural sedation reduces patients’ discomfort and anxiety, facilitating performance of the examination and intervention. However, it may also cause adverse events, including airway obstruction and hypoxia. We conducted this systematic review and meta-analysis to evaluate the efficacy of high-flow nasal oxygenation (HFNO) compared with that of standard oxygen therapy in adult patients undergoing procedural sedation. Methods We identified randomized controlled trials published before November 2020 based on PubMed, Embase, and Cochrane Library databases and ClinicalTrials.gov registry. Intraprocedural desaturation [peripheral oxygen saturation (SpO2) < 90%] was evaluated as the primary outcome. The secondary outcomes were the lowest SpO2, need for airway intervention, oxygen therapy-related complications, and patient, operator, and anesthetist’s satisfaction. Results Six trials with a total of 2633 patients were reviewed. Patients using HFNO compared with standard oxygen therapy had a significantly lower risk of intraprocedural desaturation [risk ratio 0.18, 95% confidence interval (CI) 0.04-0.87]. The lowest intraprocedural SpO2 in HFNO group was significantly higher than that in standard oxygen therapy group (mean difference 4.19%, 95% CI 1.74-6.65). Conclusions Compared with standard oxygen therapy, HFNO may reduce the risk of desaturation and increase the lowest SpO2 in adult patients undergoing sedation for medical procedures.


Sign in / Sign up

Export Citation Format

Share Document